Digestive Diseases and Sciences

, Volume 56, Issue 2, pp 376–386

CD4+CD25+ Regulatory T Cells Suppress Th17-Responses in an Experimental Colitis Model

  • Haruei Ogino
  • Kazuhiko Nakamura
  • Eikich Ihara
  • Hirotada Akiho
  • Ryoichi Takayanagi
Original Article



After the recent discovery of Th17 cells, it was proposed that Th17 responses are involved in the pathogenesis of inflammatory bowel diseases (IBD). CD4+CD25+ regulatory T cells (Treg) are considered to be an attractive tool for the treatment of IBD. Here, we investigated whether Treg are capable of suppressing Th17-mediated colitis.


Naive CD4+ T cells were transferred into SCID mice with or without Treg. In some experiments, Treg were transferred into recipient mice with established colitis. Mice treated with Treg were injected with an anti-transforming growth factor (TGF)-β mAb or control IgG. Clinical symptoms of colitis, histological changes and cytokine expressions were investigated.


SCID mice transferred with naive CD4+ T cells developed chronic colitis with significant increases in Th1 and Th17 cytokine expressions in the colon. When Treg were co-transferred with naive CD4+ T cells, development of colitis was prevented, and Th17 cytokine expressions were markedly reduced. Similarly, when Treg were transferred into mice with established colitis, the colitis was significantly ameliorated in association with dramatic reductions in Th17 cytokine expressions. Injection of anti-TGF-β mAb abolished the Treg-mediated suppression with significant elevations in Th17 cytokine productions.


This adoptive transfer model of colitis was associated with augmented Th1 and Th17 responses, and Treg were capable of suppressing colonic inflammation by downregulating Th17 responses as well as Th1 responses via TGF-β. Consequently, Treg transfer therapy is expected to be efficacious for IBD even if Th17 is involved in the pathogenesis.


Colitis model Inflammatory bowel diseases Regulatory T cells T helper 17 cells Transforming growth factor-β 


  1. 1.
    Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514–521.CrossRefPubMedGoogle Scholar
  2. 2.
    Mosmann T, Cherwinski RH, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348–2357.PubMedGoogle Scholar
  3. 3.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immuno. 2003;3:521–533.CrossRefGoogle Scholar
  4. 4.
    Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol. 2000;165:6107–6115.PubMedGoogle Scholar
  5. 5.
    Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566–573.PubMedGoogle Scholar
  6. 6.
    Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171:6173–6177.PubMedGoogle Scholar
  7. 7.
    Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316.CrossRefPubMedGoogle Scholar
  8. 8.
    Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–2370.CrossRefPubMedGoogle Scholar
  9. 9.
    Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57:1682–1689.CrossRefPubMedGoogle Scholar
  10. 10.
    Hölttä V, Klemetti P, Sippone T, et al. IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis. 2008;14:1175–1184.CrossRefPubMedGoogle Scholar
  11. 11.
    Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–458.CrossRefPubMedGoogle Scholar
  12. 12.
    Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969–1980.CrossRefPubMedGoogle Scholar
  13. 13.
    Thornton AM, Shevach EM. CD25+CD4+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287–296.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med. 2001;194:629–644.CrossRefPubMedGoogle Scholar
  15. 15.
    Nakamura K, Kitani A, Fuss I, et al. TGF-β1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol. 2004;172:834–842.PubMedGoogle Scholar
  16. 16.
    Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295–302.CrossRefPubMedGoogle Scholar
  17. 17.
    Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995–1004.CrossRefPubMedGoogle Scholar
  18. 18.
    Xu D, Liu H, Komai-Koma M, et al. CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol. 2003;170:394–399.PubMedGoogle Scholar
  19. 19.
    Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003;170:3939–3943.PubMedGoogle Scholar
  20. 20.
    Sumida Y, Nakamura K, Kanayama K, Akiho H, Teshima T, Takayanagi R. Preparation of functionally preserved CD4+CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy. Cytotherapy. 2008;10:698–710.CrossRefPubMedGoogle Scholar
  21. 21.
    Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature. 2006;441:231–234.CrossRefPubMedGoogle Scholar
  22. 22.
    Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.CrossRefPubMedGoogle Scholar
  23. 23.
    Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189.CrossRefPubMedGoogle Scholar
  24. 24.
    Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol. 1993;5:1461–1471.CrossRefPubMedGoogle Scholar
  25. 25.
    Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553–562.CrossRefPubMedGoogle Scholar
  26. 26.
    Izcue A, Hue S, Buonocore S, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559–570.CrossRefPubMedGoogle Scholar
  27. 27.
    Mudter J, Wirtz S, Galle PR, Neurath MF. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology. 2002;70:170–176.CrossRefPubMedGoogle Scholar
  28. 28.
    Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor β induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006;55:671–680.CrossRefPubMedGoogle Scholar
  29. 29.
    Harren M, Barmeyer C, Schmitz H, et al. Enhanced expression of iNOS in inflamed colons of IL-2-deficient mice does not impair colonic epithelial barrier function. Ann N Y Acad Sci. 2000;915:204–213.CrossRefPubMedGoogle Scholar
  30. 30.
    Revaz V, Debonneville A, Bobst M, Nardelli-Haefliger D. Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. Clin Vaccin Immunol. 2008;15:757–764.CrossRefGoogle Scholar
  31. 31.
    Honda K, Nakamura K, Matsui N, et al. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis. 2005;11:1044–1052.CrossRefPubMedGoogle Scholar
  32. 32.
    Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming growth factor (TGF)-β1-producing regulatory T cells induce smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1-mediated fibrosis. J Exp Med. 2003;198:1179–1188.CrossRefPubMedGoogle Scholar
  33. 33.
    Leppkes M, Becker C, Ivanov II, et al. ROR-γ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology. 2009;136:257–267.CrossRefPubMedGoogle Scholar
  34. 34.
    O’Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nature immunology. 2009;10:603–609.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-β, and CTLA4. J Immunol. 2003;171:5012–5017.PubMedGoogle Scholar
  36. 36.
    Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26:579–591.CrossRefPubMedGoogle Scholar
  37. 37.
    Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171–181.CrossRefPubMedGoogle Scholar
  38. 38.
    Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–309.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Haruei Ogino
    • 1
  • Kazuhiko Nakamura
    • 1
  • Eikich Ihara
    • 1
  • Hirotada Akiho
    • 1
  • Ryoichi Takayanagi
    • 1
  1. 1.Department of Medicine and Bioregulatory Science, Graduate School of Medical SciencesKyushu UniversityHigashi-ku, FukuokaJapan

Personalised recommendations